Business context and reporting period
Waterdrop Inc. filed this Form 20-F for the fiscal year ended December 31, 2022. Although the request specifies 2022 Q4, this filing reports annual results; it does not provide a clear standalone fourth-quarter income statement or cash-flow summary. Waterdrop operates insurance brokerage, medical crowdfunding and healthcare services primarily in China. Its Cayman Islands parent relies on PRC subsidiaries and contractual arrangements with VIEs; the filing says VIEs contributed 93.6% of 2022 net revenue, but elsewhere gives a conflicting 99.6% figure.
Financial and operating performance
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Net revenue | RMB2.802 billion | RMB3.206 billion |
| Operating profit/(loss) | RMB478.0 million | (RMB1.863 billion) |
| Net profit/(loss) | RMB607.7 million | (RMB1.574 billion) |
| Operating cash flow | RMB765.7 million | (RMB1.097 billion) |
| Cash and cash equivalents, year-end | RMB1.574 billion | RMB817.7 million |
| Restricted cash, year-end | RMB517.4 million | RMB667.7 million |
| Short-term investments, year-end | RMB2.130 billion | RMB1.969 billion |
| Total assets / total liabilities, year-end | RMB5.922 billion / RMB1.156 billion | RMB5.251 billion / RMB1.277 billion |
Reported operating and net margins were 17.1% and 21.7%, respectively, versus operating and net losses in 2021. No clear total-debt balance is stated in the supplied filing text; reported liabilities include insurance premium payables, accrued liabilities and lease obligations. Year-end cash plus short-term investments totaled approximately RMB3.705 billion, excluding RMB517.4 million of restricted cash. Management said available cash should cover working capital and capital expenditure needs for at least 12 months.
Material changes versus the prior comparable period
- Revenue fell 12.6% year over year, driven mainly by lower insurance brokerage income, down 17.1% to RMB2.343 billion.
- First-year premiums generated through the platform fell from RMB16.363 billion to RMB6.890 billion. The company attributed the decline principally to reduced dependence on third-party user-acquisition channels and fewer new consumers.
- Sales and marketing expenses fell 79.9% to RMB624.5 million; total operating costs and expenses fell 54.2% to RMB2.324 billion. The resulting return to operating profit and net profit followed substantial cost reductions.
- Revenue sources broadened: crowdfunding service fees were RMB155.8 million after fees began in April 2022; digital clinical-trial revenue rose to RMB59.5 million from RMB0.6 million, with 2,846 patients enrolled in 2022.
- Long-term insurance represented 28.8% of FYP in 2022, up from 16.2% in 2021, although long-term health and life FYP itself declined to RMB1.983 billion from RMB2.646 billion.
- Operating cash flow swung to positive RMB765.7 million. The filing attributes the improvement partly to profitability and working-capital movements, including lower insurance premium payables and contract assets.
Outlook, commentary, risks and unusual items
- Management expects cash on hand to meet anticipated needs for at least 12 months, but gives no quantified revenue, earnings or margin guidance. It says insurance FYP and revenue may decline in the foreseeable future amid macroeconomic, industry and regulatory conditions.
- Management plans to develop healthcare services, clinical-trial recruitment, technology and partnerships, while improving user engagement and reducing reliance on external acquisition channels; success is not assured.
- Key risks include PRC regulatory change and enforcement, the VIE structure and its contractual enforceability, restrictions on moving cash from China, data privacy and cybersecurity requirements, dependence on insurers and Tencent-related platforms, and competition.
- The company disclosed regulatory non-compliance findings and administrative penalties, including a June 2022 penalty; the penalty amount is not clearly provided in the filing text. It says the identified matters were rectified.
- The IPO-related shareholder class action was dismissed with prejudice in February 2023; the lead plaintiff appealed in March 2023. The company said it could not estimate any possible loss.
- Waterdrop accrued RMB15.0 million for eligible medical-expense coverage and RMB101.3 million for complementary insurance tied to the 2021 Mutual Aid business closure. Share repurchases totaled RMB67.0 million in 2022.
- The company believes it was a PFIC for U.S. tax purposes in 2022 and likely would remain one for 2023, potentially creating adverse tax consequences for U.S. holders. PCAOB inspection access to its auditor had been restored by December 2022, but future access remains a risk.
Important facts for investors to verify
- Confirm the requested Q4 scope: this 20-F provides annual FY2022 results, not a clear standalone Q4 performance breakdown.
- Resolve the filing’s conflicting statement that VIEs contributed 93.6% versus 99.6% of 2022 revenue.
- Assess the durability and composition of 2022 profit and cash generation after the sharp marketing-cost reductions, including working-capital effects and other income.
- Review the trend in FYP, brokerage revenue, long-term policy sales, customer acquisition and insurer/customer concentration.
- Check the status and financial exposure of the shareholder appeal, regulatory penalties, VIE-related risks, and China cash-transfer restrictions.